Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 1 35 28 versus PIRMELLA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 1 35 28 versus PIRMELLA 7 7 7.
NORTREL 1/35-28 vs PIRMELLA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone inhibits gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additionally, increases cervical mucus viscosity and alters endometrial receptivity.
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 28 days, followed by a 7-day placebo period (if using 28-day pack) or continuous if using 21-day pack with 7-day off. Start on first day of menstrual period.
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
None Documented
None Documented
Norethindrone: 5-14 hours (terminal); ethinyl estradiol: 13-27 hours (terminal). Context: steady-state after 5-7 days; dose adjustment in hepatic impairment.
Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days.
Renal 60-70% (as glucuronide and sulfate conjugates), fecal 20-30% (via biliary excretion).
Renal: 70% unchanged; fecal: 30% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive